荃信生物-B宣布,其新药Crusekitug(QX002n)用于治疗成人活动性强直性脊柱炎的上市申请已获得中国国家药品监督管理局正式受理。这一进展标志着公司在自身免疫疾病治疗领域的研发管线取得重要突破。
荃信生物-B宣布,其新药Crusekitug(QX002n)用于治疗成人活动性强直性脊柱炎的上市申请已获得中国国家药品监督管理局正式受理。这一进展标志着公司在自身免疫疾病治疗领域的研发管线取得重要突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.